Menu

Lab Test

Coagulation Profile

Factor V Leiden Mutation

Genetic test for a common inherited disorder that increases the risk of DVT and PE.

Normal Range
Negative
Estimated Cost
Not specified
Book Diagnostic Visit
Medical Disclaimer The information provided in this comprehensive diagnostic guide is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician regarding test results.

Factor V Leiden Mutation: A Comprehensive Medical SEO Guide

1. Comprehensive Introduction & Overview

The Factor V Leiden mutation stands as the most common inherited cause of thrombophilia, a condition characterized by an increased tendency to form blood clots. Discovered in 1994, this genetic alteration significantly impacts the delicate balance of the coagulation cascade, predisposing affected individuals to venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).

At its core, Factor V Leiden is a point mutation in the F5 gene, which codes for coagulation factor V. This specific mutation (G1691A) results in a modified Factor V protein that is resistant to inactivation by activated protein C (APC). Normally, APC acts as a crucial anticoagulant, cleaving and inactivating Factor Va and Factor VIIIa, thereby dampening the coagulation process. With Factor V Leiden, this crucial "off switch" is impaired, leading to prolonged activity of Factor Va and an increased, uncontrolled generation of thrombin, ultimately promoting clot formation.

This comprehensive guide is designed to provide an exhaustive understanding of the Factor V Leiden mutation, from its underlying genetic mechanisms and diagnostic methodologies to its extensive clinical implications, management strategies, and frequently asked questions. As expert Medical SEO Copywriters and Orthopedic Specialists, we aim to deliver an authoritative resource for patients, healthcare providers, and anyone seeking in-depth knowledge about this significant thrombophilic disorder.

2. Deep-dive into Technical Specifications & Mechanisms

What the Test Measures

The Factor V Leiden test primarily measures the presence or absence of the specific G1691A point mutation in the F5 gene. This mutation leads to the substitution of arginine with glutamine at position 506 (Arg506Gln) in the Factor V protein, rendering it resistant to cleavage by activated protein C.

There are generally two main types of tests used:

  1. Activated Protein C (APC) Resistance Assay (Screening Test):

    • This is a functional clotting assay that measures the ability of APC to prolong the clotting time in a patient's plasma.
    • In individuals with Factor V Leiden, the clotting time is less prolonged by APC compared to normal plasma, indicating APC resistance.
    • An APC resistance ratio (clotting time with APC / clotting time without APC) is calculated. A lower ratio indicates resistance.
    • It serves as a screening tool, as other conditions can also cause acquired APC resistance.

  2. Genetic Testing (Confirmatory Test):

    • This molecular test directly detects the G1691A mutation in the F5 gene using techniques such as Polymerase Chain Reaction (PCR).
    • It identifies whether an individual is homozygous (two copies of the mutated gene) or heterozygous (one copy of the mutated gene) for Factor V Leiden.
    • This test is definitive and is not affected by anticoagulants or other factors that can interfere with the functional APC resistance assay.

Mechanism of Action: The Coagulation Cascade Imbalance

The coagulation cascade is a finely tuned system of enzymatic reactions designed to stop bleeding. Factor V plays a crucial role as a cofactor in the prothrombinase complex, which converts prothrombin into thrombin, the enzyme responsible for fibrin clot formation.

  • Normal Coagulation: When Factor V is activated (Factor Va), it combines with Factor Xa, calcium, and phospholipids to form the prothrombinase complex. This complex efficiently generates thrombin. To prevent excessive clotting, activated protein C (APC), in conjunction with protein S, cleaves and inactivates Factor Va and Factor VIIIa, effectively slowing down thrombin generation.
  • Factor V Leiden Mutation: The G1691A mutation in Factor V makes it resistant to cleavage by APC. This means that Factor Va Leiden remains active for a longer duration, leading to:
    • Prolonged Thrombin Generation: The prothrombinase complex remains active for an extended period.
    • Increased Fibrin Formation: More thrombin leads to more fibrin, forming a more robust and persistent clot.
    • Prothrombotic State: The delicate balance shifts towards clot formation, increasing the risk of VTE.

The clinical risk is significantly higher for individuals who are homozygous for the mutation compared to those who are heterozygous, as they produce only the resistant form of Factor V.

3. Extensive Clinical Indications & Usage

Testing for Factor V Leiden is not routinely recommended for the general population but is indicated in specific clinical scenarios where the risk of VTE is elevated or a thrombophilic cause is suspected.

Primary Indications for Factor V Leiden Testing:

  • Unprovoked Venous Thromboembolism (VTE):
    • A first episode of DVT or PE that occurs without an obvious precipitating factor (e.g., surgery, trauma, prolonged immobilization).
  • Recurrent VTE:
    • Multiple episodes of DVT or PE, particularly if unprovoked.
  • VTE at a Young Age:
    • First VTE occurring before the age of 50 years.
  • VTE in Unusual Sites:
    • Thrombosis occurring in less common locations such as cerebral veins (stroke), mesenteric veins, portal vein, or renal veins.
  • Strong Family History of VTE:
    • Multiple first-degree relatives (parents, siblings, children) with a history of VTE, especially if they also experienced unprovoked clots or clots at a young age.
    • Known Factor V Leiden mutation in a first-degree relative who has had VTE.
  • VTE Associated with Weak Risk Factors:
    • Clotting events triggered by relatively minor risk factors like oral contraceptive use, hormone replacement therapy, or pregnancy.
  • Warfarin-Induced Skin Necrosis:
    • A rare but serious complication of warfarin initiation, which can occur in individuals with protein C or S deficiency, or less commonly, Factor V Leiden, due to an initial procoagulant state.
  • Preeclampsia, Eclampsia, or HELLP Syndrome (Controversial):
    • While some studies suggest a link, routine screening for Factor V Leiden in these conditions is not universally recommended due to insufficient evidence of clinical benefit.
  • Recurrent Miscarriage or Stillbirth (Controversial):
    • Similar to preeclampsia, the role of Factor V Leiden in recurrent pregnancy loss is debated, and routine testing is not generally recommended in the absence of a personal history of VTE.
  • Pre-Surgical Risk Assessment (Selective):
    • Consideration in patients with a strong personal or family history of VTE and other compounding risk factors prior to major surgery, though routine screening for all surgical patients is not advised.

Table of Clinical Indications

| Indication Category | Specific Clinical Scenarios The most common cause of inherited thrombophilia, Factor V Leiden, is a genetic mutation that increases the risk of developing blood clots. This guide provides comprehensive information on what the Factor V Leiden mutation is, who should be tested, how it's diagnosed, and its clinical implications.

4. Reference Ranges & Interpretation

For Factor V Leiden, "reference ranges" are not about a continuous numerical value but rather about the presence or absence of the specific genetic mutation.

For Genetic Testing (PCR-based):

The results for genetic testing are typically reported as:

  • Normal (Wild Type): No Factor V Leiden mutation detected. The individual has two normal copies of the F5 gene.
  • Heterozygous: One copy of the Factor V Leiden mutation detected (G1691A). The individual has one normal F5 gene and one mutated F5 gene. This carries an increased risk for VTE, typically 3-8 times higher than the general population.
  • Homozygous: Two copies of the Factor V Leiden mutation detected (G1691A). The individual has two mutated F5 genes. This carries a significantly higher risk for VTE, typically 50-80 times higher than the general population.

For Activated Protein C (APC) Resistance Assay (Screening Test):

The result is usually reported as an APC ratio or an interpretation of resistance.

  • Normal APC Ratio: Typically >2.0 to 2.5 (ratio can vary slightly by laboratory and method). This indicates normal sensitivity to activated protein C.
  • Reduced APC Ratio: A ratio below the laboratory's established cut-off (e.g., <2.0 or <2.5) suggests APC resistance. This result warrants confirmatory genetic testing for Factor V Leiden.

Important Note: A low APC ratio indicates APC resistance, but not all APC resistance is due to Factor V Leiden. Other factors can cause acquired APC resistance, making genetic testing crucial for definitive diagnosis.

Table of Interpretation

| Test Type | Result | Interpretation ## 5. Risks, Side Effects, or Contraindications

Understanding the risks and implications associated with Factor V Leiden is crucial for both testing and living with the diagnosis.

Risks and Side Effects of Factor V Leiden

Share this guide: